Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Completed · Phase 4

Conditions studied: Glaucoma, Ocular Hypertension

In brief

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

Key facts

Study ID

NCT00440141

Run by

Allergan

People needed

40

Starts

2006-07-01

Expected to finish

2007-03-01

Last updated by the study team

2008-01-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Glaucoma or ocular hypertension in both eyes
• Currently being treated with latanoprost 0.005% QD
• IOP greater than or equal to 18mm Hg on latanoprost 0.005%
• Best-corrected VA of 20/200 or better in each eye
• Visual field within 6 months of study entry

You may not qualify if…

• Secondary glaucoma
• Active intraocular inflammation or macular edema
• Intraocular surgery or laser surgery within the past 3 months

Where it is running

• Study site — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.